Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Tuesday 05 March, 2019

Evgen Pharma PLC

SFX-01 data published in peer reviewed journal

RNS Number : 8089R
Evgen Pharma PLC
05 March 2019
 

 

For immediate release

5 March 2019

 

 

 

 

 

Evgen Pharma plc

("Evgen Pharma" or "the Company")

 

SFX-01 data published in Peer Reviewed Journal

Evgen's SFX-01 reduces residual disability in a model of relapsing-remitting multiple sclerosis

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the publication in a peer-reviewed scientific journal showing that its lead product, SFX-01, reduced residual disability in a model of relapsing-remitting multiple sclerosis ("MS").

The paper, "SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis", has been published in the journal Multiple Sclerosis and Related Disorders and describes the work undertaken by researchers to test the efficacy of SFX-01 in murine relapsing experimental autoimmune encephalomyelitis, a model of MS. The data demonstrated that SFX-01 reduced residual disability both prophylactically and after disease induction. Most of this effect was mediated by a decrease in maximum severity of relapses and improved recovery during follow-up. Histological examination of the spinal cord was consistent with the clinical findings, with improvement in demyelination and the number of apoptotic cells, but not inflammatory cell infiltration.

The publication follows Evgen's presentation of its preclinical study data of SFX-01 in various models of the relapsing remitting form of multiple sclerosis at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) .

The paper can be viewed at: https://www.msard-journal.com/article/S2211-0348(19)30104-X/fulltext (Ian Galea et al; SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis, Multiple Sclerosis and Related Disorders, 2019).

Steve Franklin, CEO of Evgen Pharma, commented:

"The leading product in MS treatment generates revenues of several billion dollars per annum despite an adverse side effect profile. There is an attractive opportunity for oral disease-modifying agents with comparable or better efficacy and an improved side-effect profile."

Ian Galea, Associate Professor in Experimental Neurology, who leads the Southampton Clinical and Experimental Neurology Team (http://go.soton.ac.uk/6ya) at the University of Southampton, said:

"We remain excited by the potential of SFX-01 for relapsing remitting multiple sclerosis, and also the secondary progressive form of the disease. On the back of this data, we will work with Evgen to explore all sources of charitable, grant and commercial funding to ensure that this opportunity is progressed."

 

 

 

Enquiries:

 

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

 

c/o +44 (0) 20 7466 5000

finnCap

Geoff Nash, Teddy Whiley (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

www.finncap.com

 

+44 (0) 20 7220 0500

WG Partners LLP

Nigel Barnes, Claes Spång

 

+44 (0) 20 3705 9330

Buchanan

Mark Court, Sophie Wills, Tilly Abraham

[email protected]

 

 +44 (0) 20 7466 5000

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKQDPCBKDKNK

a d v e r t i s e m e n t